Compare Stocks → New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADMSNASDAQ:AGLENASDAQ:PLXPNASDAQ:PRQRNASDAQ:RAIN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMSAdamas Pharmaceuticals$8.22$8.17$4.02▼$9.15$376.37M2.82692,487 shsN/AAGLEAeglea BioTherapeutics$11.47$2.66▼$32.75$48.64M2.5795,409 shs43,300 shsPLXPPLx Pharma$0.00$0.02▼$0.04$603K3.7912.96 million shs3,000 shsPRQRProQR Therapeutics$1.86-2.1%$2.14$1.11▼$3.29$154.57M0.21148,298 shs182,612 shsRAINRain Oncology$1.21$1.21$0.82▼$11.32$44.02M0.27550,818 shsN/A7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMSAdamas Pharmaceuticals0.00%0.00%0.00%0.00%0.00%AGLEAeglea BioTherapeutics0.00%0.00%0.00%0.00%+200.25%PLXPPLx Pharma0.00%0.00%0.00%0.00%-99.29%PRQRProQR Therapeutics-2.11%-19.13%-25.90%-10.58%-16.59%RAINRain Oncology0.00%0.00%0.00%-1.63%-83.82%This consistently signaled gains of 453%... 610%... and even 1036%... (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APLXPPLx PharmaN/AN/AN/AN/AN/AN/AN/AN/APRQRProQR Therapeutics1.7143 of 5 stars3.54.00.00.02.80.00.0RAINRain OncologyN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMSAdamas PharmaceuticalsN/AN/AN/AN/AAGLEAeglea BioTherapeutics2.50Moderate Buy$17.50∞ UpsidePLXPPLx PharmaN/AN/AN/AN/APRQRProQR Therapeutics3.00Buy$3.6093.55% UpsideRAINRain Oncology2.00HoldN/AN/ACurrent Analyst RatingsLatest PLXP, ADMS, AGLE, PRQR, and RAIN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024PRQRProQR TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.80 ➝ $2.003/14/2024PRQRProQR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.00 ➝ $2.503/14/2024PRQRProQR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMSAdamas Pharmaceuticals$74.46M5.05N/AN/A($0.47) per share-17.49AGLEAeglea BioTherapeutics$2.33M0.00N/AN/A($60.61) per share0.00PLXPPLx Pharma$4.54M0.00N/AN/A$1.30 per share0.00PRQRProQR Therapeutics$7.05M21.47N/AN/A$0.55 per share3.38RAINRain OncologyN/AN/AN/AN/A$3.11 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMSAdamas Pharmaceuticals-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/AAGLEAeglea BioTherapeutics-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/APLXPPLx Pharma-$46.13M-$1.85N/AN/AN/A-606.91%-291.11%-119.43%N/APRQRProQR Therapeutics-$30.43M-$0.39N/AN/AN/A-431.65%-56.71%-19.15%5/21/2024 (Estimated)RAINRain Oncology-$75.72M-$2.06N/AN/AN/AN/A-82.96%-68.31%N/ALatest PLXP, ADMS, AGLE, PRQR, and RAIN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/13/2024Q4 2023PRQRProQR Therapeutics-$0.08-$0.08N/A-$0.08$27.88 million$3.54 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/APLXPPLx PharmaN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ARAINRain OncologyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMSAdamas Pharmaceuticals21.254.534.17AGLEAeglea BioTherapeuticsN/A4.594.59PLXPPLx PharmaN/A4.794.28PRQRProQR Therapeutics0.103.543.54RAINRain OncologyN/A5.585.58OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMSAdamas Pharmaceuticals69.97%AGLEAeglea BioTherapeuticsN/APLXPPLx Pharma21.19%PRQRProQR Therapeutics32.65%RAINRain Oncology65.84%Insider OwnershipCompanyInsider OwnershipADMSAdamas Pharmaceuticals18.90%AGLEAeglea BioTherapeutics6.60%PLXPPLx Pharma8.95%PRQRProQR Therapeutics8.40%RAINRain Oncology17.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADMSAdamas Pharmaceuticals13845.79 million37.13 millionOptionableAGLEAeglea BioTherapeutics694.05 million3.78 millionOptionablePLXPPLx Pharma1629.14 million26.53 millionNot OptionablePRQRProQR Therapeutics15681.36 million74.52 millionOptionableRAINRain Oncology6336.38 million30.05 millionOptionablePLXP, ADMS, AGLE, PRQR, and RAIN HeadlinesSourceHeadlinePeople genuinely don’t recognise film star in new make-up free selfiemetro.co.uk - April 18 at 8:01 PMYoung artist raises money for cancer researchcounton2.com - April 18 at 8:01 PMColleen Bready's forecast: Rain and snow continuingwinnipeg.ctvnews.ca - April 18 at 3:01 PMPrince William returns to public duties for first time since Kate's cancer diagnosisomaha.com - April 18 at 3:01 PMWhere the original five Oasis members are now - heart attack, divorces and tonsil cancermirror.co.uk - April 18 at 3:01 PMPrince William makes first public appearance since Kate’s cancer diagnosismsn.com - April 18 at 9:57 AMRain chances continue into tomorrowwearegreenbay.com - April 17 at 10:33 PMCovenant Health joined us with more on their Lung Cancer Screening Programeverythinglubbock.com - April 17 at 5:33 PMAsian Champions League semifinal postponed in UAE after heavy rain floodingnaharnet.com - April 17 at 7:32 AMRain washes away tonight’s Chicago White Sox game vs. the Kansas City Royalsuk.sports.yahoo.com - April 16 at 9:10 PMSpringtime brings rain, flowers and pests to Lubbockeverythinglubbock.com - April 16 at 9:10 PMMango farmers worry over forecast of raintimesofindia.indiatimes.com - April 15 at 10:28 PMThe warmest temperatures so far this year & rain chances lurkingwjcl.com - April 15 at 10:28 PMAfter wind, cold and rain, Logan Invite welcomes sunny and warmthetelegraph.com - April 15 at 5:28 PMBrain cancer patient from Meriden completes half marathon fund-raisersolihullobserver.co.uk - April 15 at 7:27 AMSunny and much warmer this weekend; a daily chance for rain starts next weekcbs4indy.com - April 14 at 12:55 PMFounder of 'The Cure Starts Now' takes message on cancer research to Washingtonmsn.com - April 14 at 12:55 PMOJ Simpson was ‘really not feeling well’ less than 2 weeks before he died from cancer: longtime friendpagesix.com - April 13 at 3:10 PMThroat cancer; Beware of the risk factors, Survivor sounds alarm bellgraphic.com.gh - April 13 at 10:10 AMPreston lads clad in just their boxers walk 44km for testicular cancer charityblogpreston.co.uk - April 12 at 6:46 PMDeadly weather pummels much of Gulf Coast with tornadoes, torrential rainmsn.com - April 12 at 1:46 PMRain forces postponement of Twins-Tigers game. They’ll play a doubleheader on Saturdaysports.yahoo.com - April 12 at 8:45 AMRain coming to an end; sunshine returns this weekendcbs4indy.com - April 12 at 8:45 AMRain delay can’t dampen Masters patrons’ excitementwtnh.com - April 12 at 1:06 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideGold Rush: Exploring 5 Sector Giants Amidst Soaring PricesApril 4, 2024 6:10 AMView Gold Rush: Exploring 5 Sector Giants Amidst Soaring PricesAll Headlines Company DescriptionsAdamas PharmaceuticalsNASDAQ:ADMSAdamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.Aeglea BioTherapeuticsNASDAQ:AGLEAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.PLx PharmaNASDAQ:PLXPPLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.ProQR TherapeuticsNASDAQ:PRQRProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.Rain OncologyNASDAQ:RAINAs of January 26, 2024, operates as a subsidiary of Pathos AI, Inc. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.